Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $50.00 by Analysts at BMO Capital Markets
Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by BMO Capital Markets from $70.00 to $50.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the stock. Other research analysts have also issued reports about the stock. Barclays reduced their price target on shares of Intellia […]
11 Jan 05:27 · The Cerbat Gem